Cliff Asness's CRSP Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 28,372 shares of CRISPR Therapeutics AG (CRSP) worth $1.84 M, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CRSP, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 16,801 shares. Largest reduction occurred in Q2 2025, reducing 3,692 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's CRISPR Therapeutics (CRSP) Holding Value Over Time
Track share changes against reported price movement
Quarterly CRISPR Therapeutics (CRSP) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +2,201 | New Buy | 2,201 | $161.74 |
| Q3 2021 | +1,661 | Add 75.47% | 3,862 | $111.86 |
| Q4 2021 | +2,911 | Add 75.38% | 6,773 | $75.74 |
| Q1 2022 | +2,310 | Add 34.11% | 9,083 | $62.75 |
| Q2 2022 | -578 | Reduce 6.36% | 8,505 | $60.79 |
| Q3 2022 | -8,505 | Sold Out | 8,505 | $0.00 |
| Q1 2025 | +25,306 | New Buy | 25,306 | $34.03 |
| Q2 2025 | -3,692 | Reduce 14.59% | 21,614 | $48.64 |
| Q3 2025 | +6,758 | Add 31.27% | 28,372 | $64.81 |
Cliff Asness's CRISPR Therapeutics Investment FAQs
Cliff Asness first purchased CRISPR Therapeutics AG (CRSP) in Q2 2021, acquiring 2,201 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held CRISPR Therapeutics AG (CRSP) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to CRISPR Therapeutics AG (CRSP) was in Q1 2025, adding 25,306 shares worth $861,163. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 28,372 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $1.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, CRISPR Therapeutics AG (CRSP) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in CRISPR Therapeutics AG (CRSP) was 28,372 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.